



May 9, 2014

## **Aastrom Biosciences to Host First Quarter 2014 Investor Call on May 15, 2014**

ANN ARBOR, Mich., May 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, announces the following webcast:

What: Aastrom Biosciences, Inc., First Quarter 2014 Investor Call

When: Thursday, May 15, 2014 at 4:30 pm (EDT)

Where: <http://investors.aastrom.com/events.cfm>

How: -- The conference call will be available live in the Investors section of the Aastrom website at <http://investors.aastrom.com/events.cfm>. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.

-- To participate in the live call by telephone, please call (877) 312-5881 and reference Aastrom Biosciences first quarter 2014 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.

If you are unable to participate during the live call, the webcast will be available at <http://investors.aastrom.com/events.cfm> until May 15, 2015. A replay of the call will also be available until 11:59 pm (EDT) on May 19, 2014 by calling (855) 859-2056, or from outside the U.S. at (404) 537-3406. The conference ID is 44774762.

### **About Aastrom Biosciences**

Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a Phase 2b clinical trial in patients with advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com).

The Aastrom Biosciences, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=3663>

*This document contains forward-looking statements, including, without limitation, statements concerning clinical trial plans and progress, objectives and expectations, clinical activity timing, intended product development, anticipated milestones, potential advantages of our product candidates and the timing and ability of Aastrom to close the acquisition of Sanofi's Cell Therapy and Regenerative Medicine business pursuant to Aastrom's Asset Purchase Agreement with Sanofi, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with the closing of the acquisition of Sanofi's Cell Therapy and Regenerative Medicine business, clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, Quarterly Reports on Form 10-Q and other filings with the SEC. These forward-looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.*

CONTACT: Media contact:

David Salisbury

Berry & Company

[dsalisbury@berrypr.com](mailto:dsalisbury@berrypr.com)

(212) 253-8881

Investor contact:

Chad Rubin

The Trout Group

[crubin@troutgroup.com](mailto:crubin@troutgroup.com)

(646) 378-2947